Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
The firm lifted the price target on the stock to 16,500 GBp from 16,000 GBp, reiterating a Buy rating on the shares. The rating update came as the firm updated its model ahead of the company's fiscal Q1 earnings. AstraZeneca's (AZN) Dividend: Resilient, Predictable, and Built on Innovation In another development, AstraZeneca PLC (NYSE:AZN) reported on March 27 positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease. The company stated that tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations compared with placebo, in the primary population of former smokers, and in the overall population. The overall population included former and current smokers, as well as patients across all blood eosinophil counts and all stages of lung function severity. Management added that Tozorakimab is a potential first-in-class monoclonal antibody targeting interleukin-33, and was generally well tolerated
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancerBusiness Wire
- Deutsche Bank Maintains Sell on AstraZeneca (AZN) [Yahoo! Finance]Yahoo! Finance
- Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPDBusiness Wire
- Astrazeneca (AZN) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AZN&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hold" to "buy"MarketBeat
- Astrazeneca (AZN) had its "buy" rating reaffirmed by TD Cowen.MarketBeat
AZN
Sec Filings
- 4/2/26 - Form 6-K
- 4/1/26 - Form 6-K
- 3/31/26 - Form 6-K
- AZN's page on the SEC website